US Patent

US11560354 — Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof

Method of Use · Assigned to SK Biopharmaceuticals Co Ltd · Expires 2039-03-06 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a newly identified solvate form of solriamfetol hydrochloride and methods of preparing and using it to treat disorders.

USPTO Abstract

The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

Drugs covered by this patent

solriamfetol-hydrochloride (SOLRIAMFETOL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3520`	—	solriamfetol-hydrochloride
`U-3520`	—	solriamfetol-hydrochloride

Patent Metadata

Patent number: US11560354
Jurisdiction: US
Classification: Method of Use
Expires: 2039-03-06
Drug substance claim: No
Drug product claim: Yes
Assignee: SK Biopharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.